

U.S. Appl. Ser. No.: 10/054,638
Response dated 7 June 2005
Reply to Office Action of 7 December 2004

Amendments to the Specification:

Please replace paragraph [0033] with the following amended paragraph:

[0033] The immunological compositions of the present invention are made by separately preparing polysaccharide-protein conjugates from different meningococcal serogroups and then combining the conjugates. The immunological compositions of the present invention can be used as vaccines. Formulation of the vaccines of the present invention can be accomplished using art recognized methods. The vaccine compositions of the present invention may also contain one or more adjuvants. Adjuvants include, by way of example and not limitation, aluminum adjuvants, Freund's Adjuvant, BAY R1005 (N-(2-Deoxy-2-L-leucylamino- β -D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate), DC-chol (3- β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol), pcpp (e.g., Poly[bis(carboxylatophoxy)phosphazene] and/or Poly[di(carboxylatophoxy)phosphazene]), monophosphoryl lipid A, CpG (oligodeoxynucleotide motifs), saponin adjuvants e.g., (QS-7, QS-21), cholera toxin and formyl methionyl peptide. See, e.g., Vaccine Design, the Subunit and Adjuvant Approach, 1995 (M. F. Powell and M. J. Newman, eds., Plenum Press, N.Y.). The adjuvant is preferably an aluminum adjuvant, such as aluminum hydroxide or aluminum phosphate.